| Message: | 2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
MF： C22H27FN4O2.C4H6O5
MW： 532.566
CAS： 341031-54-7
Appearance: red powder
Melting point: 189 ℃ ~ 191 ℃
Loss on drying: ≤1.0%
Total impurities: ≤1.0%
Content: 99%
Packaging: 1kg aluminum foil bag or according to customer requirements
Purpose: Sunitinib malate by blocking tumor cell growth to get blood and nutrients needed to play a therapeutic role. Clinical trials show that the drug can slow the growth rate of gastrointestinal stromal tumors and renal cell tumors can be reduced
Size. Sunitinib malate is the first novel can be selectively targeted drugs against a variety of tyrosine kinase receptors, combined with the suspension of blood supply to the tumor cell anti-angiogenic and direct anti-tumor attack tumor cells
Two mechanisms. It represents the advent of a new round of targeted therapies, both directly attack the tumor, nor conventional chemotherapy toxicity.
Sunitinib malate indications are as follows:
1, imatinib mesylate between failure or intolerant gastrointestinal stromal tumors (GIST).
2, inoperable advanced renal cell carcinoma (RCC).
3, advanced pancreatic endocrine tumors.
|
my account
